New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free
Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Monday, November 9, 2026

Back to the front page

From X

@kevin__mak

Kevin Mak on X

$CMPS Lots to be excited about for the company and the space. Specifically there's been a lot of "thematic" interest in the psychedelics/psilocybin space in the last few weeks, and I expect that to continue. The most notable event recently is an article published in the New England Journal of Medicine: "FDA's New Framework for Psychedelic Drugs" (paywall) This was co-authored by Michael Davis (just named permanent director of CDER) and the FDA's top psychiatry and neuroscience reviewers. They're the group that ultimately approves/rejects COMP360 (and other psychedelic drugs). Aside from approve/reject, they will be helping negotiate/decide the "label" and essentially how permissive or strict the availability of these drugs/therapies are. The devil is in the details and hearing the FDA publicly state that they are aligned, i.e. "let's make sure these drugs get to market safely AND effectively" versus "this is weird/different, lets be extra cautious/slow with the roll out" is very important to both shareholders, and patients who could potentially be helped by these therapies. Another interesting article is here: WSJ: "Elon Musk's Inner Circle is Pouring Cash Into Making Psychedelics Mainstream" It is widely expected that COMP360 from $CMPS is going to be the first classic psychedelic (Psilocybin) drug to be approved and commercially available. Despite this being "priced in" by people who follow markets (or the industry) closely, I believe there's a good chance there's a positive public reaction to the headline when/if it comes out in the coming months. More importantly, I think we're at the very early innings of a treatment category that will be highly beneficial to a group of patients who historically have not had great treatment options. My full write on $CMPS is below, I have a $45 price target: Disclosure: Creek Drive and its affiliated funds does hold a long position in CMPS. Views expressed are current opinions for informational educational only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in bio for more important information.

Investor Letters

All letters

Seed Corn

Chiron’s failed $49 million Beaumont sale and $178 million Pinnacle acquisition leave XRN with $70 million of liquidity and medical-office…

XRN $372M
Orphan REITs 3 clicks

STRL: 80 new electricians a week

Sterling’s $4.1 billion backlog faces Texas permitting risk after a governor proposed a moratorium, while Connexion, Capital Asset Planning…

STRL $7.6B
Trade Ideas Flow 2 clicks

Roblox: Capture This Moment

Roblox’s Q3 FY26 DAUs fell year over year for the first time, while bookings declined 12% to $1.7 billion.

RBLX $35B
TSOH Investment Research 2 clicks

DoorDash and Google

DoorDash and Google.

DASH $79B
Stratechery by Ben Thompson – On the business, strategy, and impact of technology. 8 clicks

Diamond Estates: Research Note

Diamond Estates converts $4.7 million of Lassonde debentures at a 69% premium, cutting debt to $10.9 million and raising Lassonde ownership…

LSDAF $1.2B
Atrium Research - Equity Research 4 clicks

Vicor Update, Part Four

Vicor’s Federal Circuit hearing put Foxconn’s disputed patent license under pressure, reinforcing its AI server royalty model and licensing…

VICR $6.8B
CV's Substack 3 clicks
FND · long

FLOOR & DECOR HLDGS

Floor & Decor operates 281 warehouse-format stores selling hard-surface flooring and accessories nationwide.

FND $5.6B
Value Investors Club 1 click

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

YouTube 4

Blogs 15

Seeking Alpha 82 of 283

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

369 firms

Sectors

Ordered by how often our editor reaches for them.